8-K: Iris Acquisition Corp. Extends Business Combination Deadline to June 2025 Following Shareholder Approval

Iris Acquisition Corp. has extended the deadline for its business combination with Liminatus Pharma to June 30, 2025, after securing shareholder approval and amending related agreements.

Summary

• Iris Acquisition Corp. has amended its business combination agreement with Liminatus Pharma, extending the deadline for the deal to be completed to June 30, 2025.
• This extension was formalized through a seventh amendment to the Business Combination Agreement.
• A related PIPE (Private Investment in Public Equity) equity subscription agreement was also amended, extending the termination deadline for the subscriber to June 30, 2025.
• Shareholders approved an amendment to the company's charter to extend the deadline for completing a business combination to March 31, 2025, with a possible three-month extension at the board's discretion.
• At a special meeting on December 20, 2024, 98.6% of outstanding shares voted in favor of the extension amendment.
• Approximately 64,453 public shares were redeemed for cash at $11.44 per share, totaling around $672,889.32, leaving 174,477 public shares outstanding.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the repeated extensions of the business combination deadline and the redemptions of public shares, which suggest potential challenges in completing the deal. However, the shareholder approval and continued PIPE commitment provide some positive aspects.

Positives

• The extension provides additional time to complete the business combination with Liminatus Pharma.
• Shareholder approval for the extension was overwhelmingly positive, indicating strong support.
• The company has secured an extension to the PIPE agreement, maintaining investor commitment.

Negatives

• The need for multiple extensions suggests potential challenges in finalizing the business combination.
• The redemption of public shares resulted in a reduction of outstanding shares.

Risks

• The business combination may still not be completed by the new deadline.
• Further delays could lead to additional redemptions and a decrease in available capital.
• The company's ability to complete the business combination is dependent on the continued commitment of the PIPE subscriber.

Future Outlook

The company is focused on completing the business combination with Liminatus Pharma by the new deadline of June 30, 2025.

Management Comments

• The company's CEO, Sumit Mehta, signed the 8-K report on behalf of Iris Acquisition Corp.
• Chris Kim, CEO of Liminatus Pharma and Iris Parent Holding Corp., signed the amendments to the Business Combination Agreement and PIPE Subscription Agreement.

Industry Context

The extension of the business combination deadline is not uncommon in the SPAC market, where deals can face regulatory and market-related hurdles. This extension provides more time to finalize the transaction, which is a common practice in the industry.

Comparison to Industry Standards

• SPACs often require extensions to complete their business combinations, as seen with other similar companies.
• The redemption rate of 64,453 shares is relatively low compared to some SPAC transactions, indicating continued investor interest.
• The extension of the PIPE agreement is also a common practice to ensure continued funding for the transaction.

Stakeholder Impact

• Shareholders have approved the extension, but some have chosen to redeem their shares.
• The extension provides more time for the company to complete the business combination, which could benefit remaining shareholders.
• The PIPE subscriber remains committed, which is crucial for the transaction's success.

Next Steps

• The company will continue to work towards completing the business combination with Liminatus Pharma by June 30, 2025.
• The company will need to monitor the market and regulatory environment to ensure the deal can be completed.

Key Dates

Keywords

business combination, merger, acquisition, SPAC, extension, PIPE, redemption, Liminatus Pharma, Iris Acquisition Corp